MedTrace Logo

Hip Fracture Exparel Administration Trial Capsule During Hemiarthroplasty

NCT03502018 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-11-18

Study results available
· View outcomes & findings →

Summary

This study will examine the efficacy of Liposomal Bupivacaine (Exparel) in hip fracture patients undergoing hip hemiarthroplasty for femoral neck fractures through a posterior approach. Post-operative measures will be assessing pain, overall opiate use, delirium, time-to-ambulation and discharge status.

Conditions

  • Intracapsular Fracture of Femur
  • Femoral Neck Fractures
  • Hip Hemiarthroplasty

Interventions

DRUG

Bupivacaine liposome

A long-acting liposomal bupivacaine

DRUG

Saline

Saline injection used as control

Sponsors & Collaborators

  • Maimonides Medical Center

    lead OTHER

Principal Investigators

  • Daniel Komlos, MD, PhD · Maimonides Medical Center

  • Kevin Kang, MD · Maimonides Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2023-08-31
Completion
2023-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03502018 on ClinicalTrials.gov